SUShinichiro Ueda

Shinichiro Ueda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shinichiro Ueda has a total of 281 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Parity and heart failure risk in diabetic women with coronary artery disease: a multicentre cohort study

    by Yuko Fujita, Takeshi Morimoto, Koichi Node, Keiko Mekaru, Shinichiro Ueda

    Introduction: Women with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) face elevated heart failure (HF) risk compared with men. Although population-based studies have linked parity to cardiovascular outcomes, evidence is limited among women with established cardiovascular disease. We investigated the association between parity and HF hospitalization and mortality in women with T2DM and CAD. Methods: This multicentre retrospective cohort study enrolled 2314 women with T2DM and CAD from 70 hospitals between 2005 and 2022 in Japan. Participants were stratified by parity and followed for a median of 2297 days. Outcomes included HF hospitalization, all-cause mortality, acute myocardial infarction, and stroke. Cox proportional hazards models adjusted for age, cardiovascular risk factors, and medication use. Results: Women with ≥5 births had significantly higher incidences of HF hospitalization (4.90 vs 3.03 per 100 person-years) and mortality (4.85 vs 3.76 per 100 person-years) compared with <5 births. After adjustment, high parity (≥5 births) was significantly associated with HF hospitalization [hazard ratio (HR): 1.41, 95% confidence interval (CI): 1.04–1.90] but not with mortality (HR: 1.22, 95% CI: .92–1.62). No associations were observed with acute myocardial infarction or stroke. Conclusion: Among women with T2DM and CAD, high parity independently and outcome specifically predicted HF hospitalization, regardless of accumulated cardiovascular risk factors. Reproductive history should be considered in HF risk stratification even for high-risk women.

  • Open Access

    Real-World Outcomes of Patients With Non-Valvular Atrial Fibrillation on Anticoagulants Ineligible for Phase III Trials of Direct Oral Anticoagulants ― A Retrospective Cohort Study ―

    by Mayumi Higa, Takeshi Morimoto, Masayuki Ikeda, Shinichiro Ueda

    Background: Many patients with non-valvular atrial fibrillation (NVAF) on direct oral anticoagulants (DOACs) in real-world practice were ineligible for DOAC phase III trials. We aimed to determine the proportion of Japanese patients with NVAF eligible for these trials and compare the characteristics and outcomes of ineligible and eligible patients to determine the generalizability of the trial results.Methods and Results: This retrospective cohort study included 7,826 Japanese NVAF patients on warfarin from 71 hospitals. We assessed trial eligibility and analyzed outcomes (major bleeding, stroke/systemic embolism, all-cause mortality) using Cox proportional hazards models. Nearly half (48.2%; n=3,772) of the patients were ineligible for DOAC phase III trials. Ineligible patients were older with more comorbidities and exhibited significantly higher risks of death (unadjusted hazard ratio [HR] 2.84; 95% confidence interval [CI] 2.36–3.43; P<0.0001), stroke/systemic embolism (unadjusted HR 1.53; 95% CI 1.17–1.98; P=0.0016), and major bleeding (unadjusted HR 2.00; 95% CI 1.63–2.44; P<0.0001) compared with eligible patients.Conclusions: Half of the NVAF patients receiving anticoagulant therapy in real-world practice were ineligible for phase III DOAC trials, primarily due to safety concerns. This population differs substantially from eligible patients in characteristics and outcomes. The generalizability of phase III results to real-world patients remains uncertain, warranting additional assessment.


  • Open Access

    Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L

    by Miwa Kawanaka, Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, et al.

    Background/Objectives: The possibility of progressive liver fibrosis remains even when alanine aminotransferase (ALT) levels are <30 IU/L. Therefore, we aimed to investigate factors that can predict fibrosis progression in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with ALT levels ≤ 30 U/L. Methods: This multicenter retrospective cohort study was conducted using data collected between December 1994 and December 2021. Among the 1381 patients with MASLD (CLIONE study) who underwent liver biopsy, we performed decision-tree analysis on factors for stage ≥ 3 in 115 with ALT levels ≤ 30 U/L. Of the 818 patients with MASLD (Kawasaki cohort) who underwent liver biopsy, we included 174 with ALT levels ≤ 30 U/L for validation. Results: In the decision-tree analysis of patients with stage ≥ 3 with ALT levels ≤ 30 U/L, 57% of patients with a fibrosis-4 (FIB-4) index ≥ 2.67 and 70% with both FIB-4 index ≥ 2.67 and type-2 diabetes mellitus (DM) were detected. However, no cases of stage ≥ 3 were observed among patients without type-2 DM with ALT ≤ 30 U/L and a FIB-4 index < 2.67. After verifying the decision-tree analysis, the model construction and validation datasets showed a close correlation. Conclusions: Among patients with MASLD with ALT levels ≤ 30 U/L, those with an FIB-4 index ≥ 2.67, particularly with comorbid type-2 DM, should consider consultation with a hepatologist.


  • Open Access

    Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database

    by Keiko Miyazato, Hiroshi Ohtsu, Akihiko Shimomura, Naohiro Yonemoto, Chikako Shimizu, Kazuhiro Sase, Shinichiro Ueda


  • Open Access

    Factors related to the choice of warfarin for treating newly diagnosed nonvalvular atrial fibrillation are associated with safety outcomes during anticoagulation: A new‐user, active‐comparator, retrospective cohort study

    by Yoshiko Takagi, Shinichiro Ueda

    Background: Direct oral anticoagulants (DOACs) are preferred for stroke prevention in nonvalvular atrial fibrillation (NVAF); however, warfarin is still used. This study examined why physicians may choose warfarin over DOACs and the associated safety outcomes in patients with NVAF.Methods: We conducted a new‐user, active‐comparator cohort study in newly diagnosed patients with NVAF to assess safety outcomes after the introduction of DOACs in Japan.Results: The median observation period was 1120 days; 1428 patients started anticoagulation therapy with warfarin and 1551 with DOACs. Warfarin was chosen for patients with lower creatinine clearance and left ventricular ejection fractions and those using aspirin and verapamil. The unadjusted risk of major bleeding was considerably higher in the warfarin group but was nonsignificant after adjusting for variables associated with the choice of warfarin, in addition to age and sex. The risk of death was higher in the warfarin group, even after adjustments for relevant variables. However, high‐risk subgroups, including those with older ages and multiple comorbidities, such as renal impairment, for whom warfarin was more likely to be selected, had severely compromised prognoses with either anticoagulant. The risk of stroke/systemic embolism was not significantly different between the two groups.Conclusions: Warfarin is often chosen for older patients with multiple comorbidities characterized by reduced renal function, which is associated with a higher risk of major bleeding and mortality. These high‐risk patients seem to have a poor prognosis regardless of the type of anticoagulant used. Thus, safe anticoagulant therapy remains a challenge for such patients.


  • Open Access

    Early and short-term use of proprotein convertase anti-subtilisin–kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome

    by Hiroki Uehara, Takashi Kajiya, Masami Abe, Marohito Nakata, Shingo Hosogi, Shinichiro Ueda

    Aims: Proprotein convertase anti-subtilisin–kexin type 9 inhibitors (PCSK9Is) improve plaque volume and composition and reduce major adverse coronary events in chronic coronary artery disease. We evaluated the effects of the short-term use of PCSK9Is on coronary plaque stability in patients with acute coronary syndrome (ACS) using optical coherence tomography (OCT). Methods and results: This is a multicentre, open-label randomized controlled trial. The enrolled 80 subjects met the inclusion criteria. Of these, 52 patients (age 60 ± 11 years, 38 men, 14 women) with ST-elevated ACS had undergone successful primary percutaneous coronary intervention with LDL-cholesterol (LDL-C) levels > 70 mg/dL while receiving high-intensity statins. Participants were randomly assigned to the PCSK9I group (evolocumab 420 mg for 3 months, n = 29) or the standard of care (SoC) group (n = 23). Optical coherence tomography was performed at baseline (BL) and 3 and 9 months after randomization to assess lipid-rich plaques in non-culprit lesions. The change in the minimum fibrous cap thickness (MFCT) from BL to 9 months was the primary endpoint. The percentage change in LDL-C levels from BL to 3 months was significantly greater in the PCSK9I group (−67.8 ± 21.5% in the PCSK9I group vs. −16.3 ± 21.8% in the SoC group; P < 0.0001), and the difference between the two groups disappeared from BL to 9 months (−20.0 ± 37.8% in the PCSK9I group vs. −6.7 ± 34.2% in the SoC group; P = 0.20). The changes in MFCT from BL to 9 months were significantly greater in the PCSK9I group, even after PCSK9I discontinuation {100 μm [interquartile range (IQR): 45–180 μm] vs. 50 μm [IQR: 0–110 μm]; P = 0.032}. Conclusion: Combination treatment with PCSK9Is and statins resulted in more marked plaque stabilization after ACS than SoC alone, and this effect persisted for 6 months after PCSK9I discontinuation. Registration: Adage-Joto study, UMIN ID No. 26516.


  • Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease

    by Kazuhiro Nouso, Miwa Kawanaka, Hideki Fujii, Kazuya Kariyama, Hidenori Toyoda, Michihiro Iwaki, Hideki Hayashi, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, et al.

    Background and Aims: Because the accuracy of the Fibrosis‐4 (FIB‐4) index for predicting liver fibrosis changes with age, the need for different cut‐offs in various age groups has frequently been discussed. We developed the age‐independent score, the Fibrosis‐3 (FIB‐3) index, and have shown its usefulness in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study aimed to validate the diagnostic ability of the FIB‐3 index to predict fibrosis progression using a large new patient cohort.Methods: The ability of the FIB‐3 index to predict liver fibrosis was analyzed by comparing it with that of the FIB‐4 index using data from 1398 patients with MASLD enrolled in the Asia‐based clinical outcome NAFLD study.Results: The areas under the receiver operating characteristic curves for predicting fibrosis stage F3 or higher were not different between the FIB‐3 and FIB‐4 indices in the entire cohort. Using the single ideal cut‐offs of the indices (3.41 for FIB‐3 index and 2.01 for FIB‐4 index), the predictive accuracy of the FIB‐3 index was not significantly different from that of the FIB‐4 index among patients aged p < 0.0001).Conclusion: The high ability of the FIB‐3 index with a single cut‐off to predict liver fibrosis in patients with MASLD was confirmed. The FIB‐3 index could serve as a useful tool for assessing liver fibrosis regardless of age.


  • Open Access

    Outcomes of real-world patients with non-valvular atrial fibrillation on anticoagulants ineligible for Phase III trials of direct oral anticoagulants

    by Mayumi Higa, Takeshi Morinoto, Masayuki Ikeda, Shinichiro Ueda

    Aims: To compare the outcomes of real-world Japanese patients with nonvalvular atrial fibrillation who are ineligible for phase III trials of direct oral anticoagulants with those of eligible patients. Methods: In retrospective cohort design, consecutively registered patients with nonvalvular atrial fibrillation who had taken warfarin were followed up and assessed eligibility of patients for phase III trials of direct oral anticoagulants. The effects of the ineligibility of patients on outcomes were estimated using Cox proportional hazards models to calculate the hazard ratio (HR) and 95% confidence interval. Results: We registered 7826 Japanese patients with nonvalvular atrial fibrillation from 71 hospitals. Nearly half (48.2%, n=3772) of these patients were ineligible for phase III trials of direct oral anticoagulants, mainly because of low CHADS2 scores (26.4%), renal dysfunction (9.5%), anemia (6.4%), and chronic treatment with nonsteroidal anti-inflammatories (4.0%). After excluding patients with a CHADS2 score <2 (n=2064, 26.4%) from total ineligible patients, the remaining ineligible patients (n=1708) exhibited significantly greater risks of major bleeding (unadjusted hazard ratio 2.00, 95% confidence interval 1.63–2.44, p<0.0001), stroke/systemic embolism (unadjusted hazard ratio 1.53, 95% confidence interval 1.17–1.98, p=0.0016), and all-cause mortality (unadjusted hazard ratio 2.84, 95% confidence interval 2.36–3.43, p<0.0001) compared to the eligible patients. Conclusions: The benefits and risks of direct oral anticoagulants suggested by phase III trials may not necessarily apply to patients ineligible for Phase III trials. This gap between evidence and practice is an issue in the real-world safety and efficacy of anticoagulants.